The FDA authorizes nicotine pouches as a lower-risk alternative to cigarettes for adult consumers
The U.S. Food and Drug Administration recently authorized the marketing of several nicotine pouch products, specifically designating them as 'Modified Risk Tobacco Products.' This designation allows brands like ZYN to be marketed as having a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis compared to traditional cigarettes. The administration announced this move as part of a broader effort to boost the fast-growing nicotine pouch sector, which has seen monthly sales skyrocket by 250% between 2023 and 2025. While health advocates and medical experts express concern over the potential for nicotine addiction, particularly in children, the FDA maintains that the products provide clear, science-based information for adult users to make informed choices. Experts like Dr. Sunny Shukla and Dr. Bonnie Halpern-Felsher warn that while pouches are demonstrably less harmful than burning tobacco, they are not risk-free. They emphasize that nicotine still causes elevated heart rates and blood pressure, and can impact brain development in adolescents. The FDA continues to warn that there is no safe tobacco product and those who do not use tobacco should not start.